Related Experiment Videos
Henoch-Schönlein purpura
1Division of Immunology and Rheumatology, Department of Pediatrics, University of Virginia Health System, Charlottesville, Virginia 22908, USA. fts@virginia.edu
Current Opinion in Rheumatology
|January 10, 2001
Summary
Henoch-Schönlein purpura (HSP), a common childhood vasculitis, is increasingly understood through immunoglobulin A1 glycosylation abnormalities. Aberrant glycosylation of this protein plays a key role in HSP
Area of Science:
- Pediatrics
- Immunology
- Rheumatology
Background:
- Henoch-Schönlein purpura (HSP) is the most frequent vasculitis affecting children.
- While clinical features and diagnosis are established, etiology and treatment remain incompletely understood.
- Recent research highlights a gap in understanding HSP pathogenesis.
Purpose of the Study:
- To review the clinical aspects of Henoch-Schönlein purpura (HSP).
- To present new information regarding HSP therapy.
- To focus on the role of immunoglobulin A1 (IgA1) glycosylation in HSP pathogenesis.
Main Methods:
- Literature review of clinical aspects of HSP.
- Review of recent therapeutic advancements for HSP.
- Focus on recent findings regarding immunoglobulin A1 (IgA1) glycosylation abnormalities.
Main Results:
- HSP is primarily a pediatric disease, with well-documented clinical features.
- Significant gaps persist in understanding HSP etiology, pathogenesis, and treatment.
- Aberrantly glycosylated IgA1 is implicated in the pathogenesis of HSP.
Conclusions:
- HSP is the most common vasculitis in children.
- Understanding IgA1 glycosylation abnormalities offers new insights into HSP pathogenesis.
- Further research into IgA1 glycosylation may guide future HSP therapies.